About AIkido Pharma
AIkido Pharma is a publicly listed company based in New York (United States) founded in 1967. Drugs for treating pancreatic cancer and leukemia are developed. AIkido Pharma has completed 2 acquisitions, including CBM Biopharma and DatChat. Its chief executive, as recorded, is Anthony C. Hayes. AIkido Pharma offers products and services including AML and ALL Therapy, Pancreatic Cancer Therapy, Prostate Cancer Therapy, and Antiviral Platform. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is AIkido Labs Inc.
Company details
AIkido Pharma was founded in 1967 in New York, United States, within the biotechnology sector. Therapeutics for cancer treatment are developed, with pipelines targeting pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The acute myeloid leukemia drug is formulated as a targeted therapy to address multiple resistance mechanisms. Operations are centered on advancing these oncology-focused drug candidates.
- Headquarters New York, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aikidopharma.com
- Social LinkedIn X
- Legal Name Aikido Labs Inc.
- Annual Revenue$9 K (USD)as on Dec 31, 2019
- Latest Funding Round$1.46M (USD), Post-IPO
Jul 2015
- Investments & AcquisitionsCBM Biopharma
& 1 more
Products & Services of AIkido Pharma
AIkido Pharma offers a comprehensive portfolio of products and services, including AML and ALL Therapy, Pancreatic Cancer Therapy, Prostate Cancer Therapy, and Antiviral Platform.
Therapeutics targeting acute myeloid and lymphoblastic leukemia.
Treatment for pancreatic cancer based on preclinical results.
Therapeutic for prostate cancer with positive preclinical outcomes.
Broad-spectrum antiviral drugs licensed from universities.
Funding Insights of AIkido Pharma
- Total Rounds 5
- Last Round Post-IPO — $1.46M
- First Round $2.6M
(Nov 2012)
All 5 funding rounds of AIkido Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $1.46M | Post-IPO | – | – | – |
| Apr 2014 | $4.45M | Post-IPO | – | – | – |
| Nov 2013 | $2.24M | Post-IPO | – | – | – |
| Jul 2013 | $500,000 | Post-IPO | – | – | – |
| Nov 2012 | $2.6M | Post-IPO | – | – | – |
People of AIkido Pharma
10 people are tracked at AIkido Pharma (2 in leadership, 8 in board & advisors).
| Name | Role | Group |
|---|---|---|
Anthony C. Hayes | CEO | Leadership |
Bill West | Partner | Leadership |
Rana Quraishi | Advisor | Board & advisors |
David Sarnoff | Advisor | Board & advisors |
Bruce Tsuji | Advisor | Board & advisors |
Scott T. Tagawa | Advisor | Board & advisors |
Robert J. Vander Zanden | Chairman of the Board | Board & advisors |
Tim Ledwick | Director | Board & advisors |
Eric Weisblum | Director | Board & advisors |
Greg Blattner | Director | Board & advisors |
Complete people profiles for AIkido Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AIkido Pharma
AIkido Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CBM Biopharma and DatChat.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for cancer treatment are developed. | cbmbiopharmainc.com | Dallas, United States | 2018 | Jun 2019 | •••• | |
Ephemeral messaging platform offered for enterprise social networking. | datchat.com | New Brunswick, United States | 2015 | Mar 2018 | •••• |
Complete acquisition details for AIkido Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AIkido Pharma
6 dated milestones of AIkido Pharma across 52 years, from founding to its latest funding, stage changes and deals.
- Founded AIkido Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.6M.
- Funding Latest funding round, Post-IPO, of $1.5M.
- Acquisition Acquires DatChat.
- Acquisition Acquires CBM Biopharma.
Web traffic of AIkido Pharma
The website of AIkido Pharma (aikidopharma.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 2.4% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as AIkido Pharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aikido Pharma
Complete news archive for AIkido Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AIkido Pharma
AIkido Pharma was founded in 1967 and raised its 1st funding round 45 years after it was founded.
AIkido Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Anthony C. Hayes is the CEO of AIkido Pharma, as recorded in our data.
Annual revenue of AIkido Pharma is $9K as on Dec 31, 2019.
AIkido Pharma was founded in 1967 in New York, United States, within the biotechnology sector. Therapeutics for cancer treatment are developed, with pipelines targeting pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The acute myeloid leukemia drug is formulated as a targeted therapy to address multiple resistance mechanisms. Operations are centered on advancing these oncology-focused drug candidates.
AIkido Pharma offers AML and ALL Therapy, Pancreatic Cancer Therapy, Prostate Cancer Therapy, and Antiviral Platform.
AIkido Pharma has made 2 acquisitions, including CBM Biopharma, and DatChat.
AIkido Pharma operates through Aikido Labs Inc..